Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
  <li>
<a href="https://smartkarma.com/entities/city-therapeutics-inc">City Therapeutics</a>, Inc. (Nasdaq: CTY) is a clinical-stage biotechnology company pioneering next-generation RNA interference (RNAi) medicines engineered around proprietary 'cleavage-inducing tiny RNA' (cityRNA) trigger technology designed to overcome historical biodistribution and extra-hepatic delivery bottlenecks.</li>
  <li>The clinical pipeline is anchored by CITY-FXI, an investigational Phase 1 Factor XI-targeting siRNA therapeutic designed to prevent thromboembolic disorders while mitigating major hemorrhage risks, alongside near-term IND-track assets CITY-RBP4 for Stargardt disease and CITY-TFR2 for chronic anemia.</li>
  <li>Backed by premier RNAi founders, including founding Alnylam Chief Executive Dr. John Maraganore, CTY is supported by over $238.8 million in private capital, non-dilutive collaborations with Biogen (up to $1.0+ billion in total deal value) and Bausch + Lomb, and a September 2026 Nasdaq IPO filing to fund operations through Phase 2 clinical milestones.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  
City Therapeutics, Inc. (Nasdaq: CTY) is a clinical-stage biotechnology company pioneering next-generation RNA interference (RNAi) medicines engineered around proprietary 'cleavage-inducing tiny RNA' (cityRNA) trigger technology designed to overcome historical biodistribution and extra-hepatic delivery bottlenecks.
  The clinical pipeline is anchored by CITY-FXI, an investigational Phase 1 Factor XI-targeting siRNA therapeutic designed to prevent thromboembolic disorders while mitigating major hemorrhage risks, alongside near-term IND-track assets CITY-RBP4 for Stargardt disease and CITY-TFR2 for chronic anemia.
  Backed by premier RNAi founders, including founding Alnylam Chief Executive Dr. John Maraganore, CTY is supported by over $238.8 million in private capital, non-dilutive collaborations with Biogen (up to $1.0+ billion in total deal value) and Bausch + Lomb, and a September 2026 Nasdaq IPO filing to fund operations through Phase 2 clinical milestones.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: City Therapeutics (CTY US) - Oct 2026

United States

City Therapeutics, Inc. is a biotechnology company. The Company develops RNA interference therapeutics designed to silence the expression of disease-relevant proteins for the benefit of patients in need. City Therapeutics operates in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Primer: City Therapeutics (CTY US) - Oct 2026

City Therapeutics, Inc. (Nasdaq: CTY) is a clinical-stage biotechnology company pioneering next-generation RNA interference (RNAi) medicines...

αSK Primers